87 related articles for article (PubMed ID: 947956)
41. Enzymatic properties of human Hageman factor fragment with plasma prekallikrein and synthetic substrates.
Hojima Y; Tankersley DL; Miller-Andersson M; Pierce JV; Pisano JJ
Thromb Res; 1980 May 1-15; 18(3-4):417-30. PubMed ID: 6903022
[No Abstract] [Full Text] [Related]
42. Autoactivatability of human Hageman factor (factor XII).
Miller G; Silverberg M; Kaplan AP
Biochem Biophys Res Commun; 1980 Feb; 92(3):803-10. PubMed ID: 7362605
[No Abstract] [Full Text] [Related]
43. Factor XII Structure-Function Relationships.
Shamanaev A; Litvak M; Ivanov I; Srivastava P; Sun MF; Dickeson SK; Kumar S; He TZ; Gailani D
Semin Thromb Hemost; 2023 Jun; ():. PubMed ID: 37276883
[TBL] [Abstract][Full Text] [Related]
44. Structures of human plasma β-factor XIIa cocrystallized with potent inhibitors.
Dementiev A; Silva A; Yee C; Li Z; Flavin MT; Sham H; Partridge JR
Blood Adv; 2018 Mar; 2(5):549-558. PubMed ID: 29519898
[TBL] [Abstract][Full Text] [Related]
45. In vivo roles of factor XII.
Renné T; Schmaier AH; Nickel KF; Blombäck M; Maas C
Blood; 2012 Nov; 120(22):4296-303. PubMed ID: 22993391
[TBL] [Abstract][Full Text] [Related]
46. The many faces of the contact pathway and their role in thrombosis.
Woodruff RS; Sullenger B; Becker RC
J Thromb Thrombolysis; 2011 Jul; 32(1):9-20. PubMed ID: 21404067
[TBL] [Abstract][Full Text] [Related]
47. Dissemination of contact activation in plasma by plasma kallikrein.
Cochrane CG; Revak SD
J Exp Med; 1980 Sep; 152(3):608-19. PubMed ID: 6902742
[TBL] [Abstract][Full Text] [Related]
48. Guinea pig Hageman factor as a vascular permeability enhancement factor.
Yamamoto T; Cochrane CG
Am J Pathol; 1981 Nov; 105(2):164-75. PubMed ID: 6794374
[TBL] [Abstract][Full Text] [Related]
49. Inactivation of factor XII active fragment in normal plasma. Predominant role of C-1-inhibitor.
de Agostini A; Lijnen HR; Pixley RA; Colman RW; Schapira M
J Clin Invest; 1984 Jun; 73(6):1542-9. PubMed ID: 6725552
[TBL] [Abstract][Full Text] [Related]
50. Activation of rabbit Hageman factor by homogenates of cultured rabbit endothelial cells.
Wiggins RC; Loskutoff DJ; Cochrane CG; Griffin JH; Edgington TS
J Clin Invest; 1980 Jan; 65(1):197-206. PubMed ID: 6444222
[TBL] [Abstract][Full Text] [Related]
51. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment.
Ghebrehiwet B; Randazzo BP; Dunn JT; Silverberg M; Kaplan AP
J Clin Invest; 1983 May; 71(5):1450-6. PubMed ID: 6304147
[TBL] [Abstract][Full Text] [Related]
52. Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients.
Zuraw BL; Curd JG
J Clin Invest; 1986 Aug; 78(2):567-75. PubMed ID: 3734104
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of the activation of Hageman factor (factor XII) by complement subcomponent C1q.
Rehmus EH; Greene BM; Everson BA; Ratnoff OD
J Clin Invest; 1987 Aug; 80(2):516-21. PubMed ID: 3038961
[TBL] [Abstract][Full Text] [Related]
54. FXII.
Fuhrer G; Gallimore MJ; Heller W; Hoffmeister HE
Blut; 1990 Nov; 61(5):258-66. PubMed ID: 2271772
[TBL] [Abstract][Full Text] [Related]
55. Kallikreins and kinins: mediators in inflammatory joint disease?
Worthy K; Figueroa CD; Dieppe PA; Bhoola KD
Int J Exp Pathol; 1990 Aug; 71(4):587-601. PubMed ID: 2205284
[No Abstract] [Full Text] [Related]
56. Mechanisms for the involvement of high molecular weight kininogen in surface-dependent reactions of Hageman factor.
Griffin JH; Cochrane CG
Proc Natl Acad Sci U S A; 1976 Aug; 73(8):2554-8. PubMed ID: 1066663
[TBL] [Abstract][Full Text] [Related]
57. Initiation of plasma prorenin activation by Hageman factor-dependent conversion of plasma prekallikrein to kallikrein.
Sealey JE; Atlas SA; Laragh JH; Silverberg M; Kaplan AP
Proc Natl Acad Sci U S A; 1979 Nov; 76(11):5914-8. PubMed ID: 42905
[TBL] [Abstract][Full Text] [Related]
58. The relationship of structure and function in human Hageman factor. The association of enzymatic and binding activities with separate regions of the molecule.
Revak SD; Cochrane CG
J Clin Invest; 1976 Apr; 57(4):852-60. PubMed ID: 947956
[TBL] [Abstract][Full Text] [Related]
59. The binding and cleavage characteristics of human Hageman factor during contact activation. A comparison of normal plasma with plasmas deficient in factor XI, prekallikrein, or high molecular weight kininogen.
Revak SD; Cochrane CG; Griffin JH
J Clin Invest; 1977 Jun; 59(6):1167-75. PubMed ID: 864009
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
